Moteur de recherche d’entreprises européennes
Financement de l’UE (12 M €) : Understanding Gene ENvironment Interaction in ALcohol-related hepatocellular carcinoma Hor01/01/2023 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Understanding Gene ENvironment Interaction in ALcohol-related hepatocellular carcinoma
Alcohol-related hepatocellular carcinoma (ALD-HCC) is, in Europe, the leading cause of liver cancer (2nd most common cause of cancer-related death worldwide, affecting both men and women). ALD-HCC has a median 5-year survival rate of 15%. Yet, the prognosis is driven by the tumour stage, with curative options providing a 5-year survival exceeding 70% for early-stage HCC (<20% of cases). Therefore, interventions aiming to improve prevention and early detection are key. ALD-HCC results from the interplay between environmental determinants and genetic variations. A comprehensive characterisation of environmental factors (e.g. diet, lifestyle) linked to ALD-HCC is still lacking. We recently performed the 1st genome-wide association study of ALD-HCC and identified predisposing genetic variations. However, their role on alcohol-related liver carcinogenesis needs clarification and the genetic architecture of ALD-HCC remains mostly unknown. GENIAL brings together partners with unique expertise in clinical hepatology, single-cell and spatial multi-omics, artificial intelligence (AI) and communication and dissemination capacities. Our aim is to 1) portray genetic and environmental determinants promoting ALD-HCC; 2) evaluate how they interact at cellular level in human samples and preclinical models to get novel insights into liver carcinogenesis, and identify chemopreventive targets; and 3) assess how these determinants modulate the ALD-HCC risk in prospective cohorts of patients included in HCC surveillance programs. Environmental factors will be comprehensively characterised in an ongoing clinical trial designed to evaluate alternative methods for early-stage HCC detection. Finally, AI models, reaching the minimal viable product stage by the end of GENIAL, will be used to integrate genetic and non-genetic information (including digital imaging) to develop novel cost-effective strategies towards prevention and early-stage detection of ALD-HCC in at-risk individuals. This action is part of the Cancer Mission cluster of projects on ‘‘Understanding’.
| EUROPEAN Association FOR THE STUDYOF THE LIVER | ? |
| Assistance Publique Hopitaux de Paris | 1 769 425 € |
| Epsa Innovation France | 414 375 € |
| European Liver Patients Association | 83 375 € |
| Fondazione Irccs CA' Granda - Ospedale Maggiore Policlinico | 0,00 € |
| Fundacao D. Anna de Sommer Champalimaud e DR. Carlos Montez Champalimaud | 1 500 938 € |
| Institut National de la Sante et de la Recherche Medicale | 2 613 758 € |
| StratiPath AB | 667 975 € |
| TECHNISCHE UNIVERSITAET DRESDEN | 1 534 875 € |
| Universita Degli Studi Di Milano | 494 094 € |
| Universite Libre de Bruxelles | 1 306 338 € |
| Universite Paris 13 | 393 845 € |
| Universite Paris Cite | 605 000 € |
| VIB VZW | 417 219 € |
https://cordis.europa.eu/project/id/101096312
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : European Association FOR THE Study OF THE Liver, Genève, Suisse.
